Swedish biopharmaceutical company Swedish Orphan Biovitrum AB said Monday it has struck a deal to buy Arthrosi Therapeutics Inc., a U.S.-based gout specialist, in a transaction valued at up to $1.5 billion, positioning the company for a long-term expansion in gout treatments. Deal Designed to Bolster Gout Portfolio Known as Sobi and listed on the Sobi to acquire Arthrosi Therapeutics in a $1.5B gout drug deal aimed at long-term growth.
Sobi to Acquire Arthrosi Therapeutics in $1.5B Gout Drug Bet
